Article information
Full text is only aviable in PDF
References
[1]
Alzforum. Avaiable from: www.alzforum.com.
[2]
J.P. Ioannidis, G. Thomas, M.J. Daly.
Validating, augmenting and refining genome-wide association signals.
Nat Rev Genet, 10 (2009), pp. 318-329
[3]
J. Cummings.
What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?.
Biol Psychiatry, 10 (2010), pp. 876-878
[4]
C.R. Jack, D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, M.W. Weiner, et al.
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.
Lancet Neurol, 9 (2010), pp. 119-128
[5]
T.E. Goldberg, J. Koppel, L. Keehlisen, E. Christen, U. Dreses-Werringloer, C. Conejero-Goldberg, et al.
Performance-based measures of everyday function in Mild Cognitive Impairment.
Am J Psychiatry, 167 (2010), pp. 845-853
[6]
Conejero-Goldberg C, Hyde TM, Chen S, Dreses-Werringloer U, Herman M, Kleinman JE, et al. Molecular signatures in postmortem brain tissue of individuals at high risk for Alzheimer's disease. Mol Psychiatry 2010;18. (In press).
Copyright © 2011. SEP y SEPB